Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.

Matthias IlmerNachman MazurekMichael Z GilcreaseJames C ByrdWendy A WoodwardThomas A BuchholzKim AcklinKaren RamirezMargarete HafleyEckhard AltJody VykoukalRobert S Bresalier

Published in: Breast cancer research : BCR (2016)

Thus, in at least some breast cancers, loss of Gal3 might be associated with EMT and cancer stemness-associated traits, predicts poor response to chemotherapy, and poor prognosis.

Keyphrases

poor prognosis
stem cells
long non coding rna
epithelial mesenchymal transition
childhood cancer
papillary thyroid
lymph node
squamous cell
bone marrow
cell therapy
genome wide
locally advanced
squamous cell carcinoma
young adults
radiation therapy
signaling pathway
free survival
lymph node metastasis